Page 92

Sochinut_43_3

313 disease mortality risk?: evidence from an individualparticipant meta-analysis of 82 864 participants from nine cohort studies. Obes Rev. 2011;12:680–7. 25. Sanchis-Gomar F, Pérez-Quilis C. Irisinemia: a novel concept to coin in clinical medicine? Ann Nutr Metab. 2013;63:60–1. 26. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol Rev. 2004;84: 277–359. 27. Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest. 2002; 25:823–35. 28. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab. 2007;293:444 - 52. 29. Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein 1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell. J Biol Chem. 2001;276:1486–93. 30. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, Qi L, Zhang M, Wang X, Cui T, Yang L, i Tang D. Irisin Stimulates Browning of White Adipocytes Through Mitogen-Activated Protein Kinase p38 MAP Kinase and ERK MAP Kinase Signaling.Diabetes 2014;63:514–25. 31. Tsuchiya Y, Ando D, Goto K, Kiuchi M, Yamakita M, Koyama K. High-Intensity Exercise causes Greater Irisin Response Compared With Low-Intensity Exercise under Similar Energy Consumption. Tohoku J Exp Med. 2014; 233:135 - 40. 32. Enerbäck S. Brown adipose tissue in humans. IntJ Obes (Lond) 2010;34(Suppl.1):S43-6. 33. Lidell ME, Enerbäck S. Brown adipose tissue - a new role in humans. Nat Rev Endocrinol. 2010;6:319–25. 34. Aydin S. Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cows. Peptides 2013;43:83–7. 35. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD. Mitochondrial proton and electron leaks. Essays Biochem. 2010;47:53–67. 36. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012;61:1725–38. 37. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 2013;39:125–30. 38. Gutierrez C, Garcia S, Rodrigez F, Garcia E, Haro J, Garcia J, Valdes S, Gonzalo M, Soriguer F, Moreno F, Rodriguez A, Martinez A, Santoyo J, Perez V, Garcia E. FNDC5 could be regulated by leptin in adipose tissue. Eur J Clin Invest. 2014;44(10): 918-25. 39. Liu jj, Wong MD, Toy WC, Tan CS, Liu S, NG XW, Tavintharan S, Sum CF, Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365-69. 40. Choi YK, Kim MK, Bae KH, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. Serum irisin levels in new onset type 2 diabetes. Diabetes Res Clin Pract. 2013; 100:96-101. 41. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98(12):4899–907. 42. Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA, Perticone F. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol. 2014;51(5):705–13. 43. Garcés MF, Peralta JJ, Ruiz-Linares CE, Lozano AR, Poveda NE, Torres-Sierra AL, Eslava-Schmalbach JH, Alzate JP, Sánchez AY, Sanchez E, Angel-Müller E, Ruíz-Parra AI, Diéguez C, Nogueiras R, Caminos JE. Irisin levels during pregnancy and changes associated with the development of preeclampsia. J Clin Endocrinol Metab. 2014;99(6):2113–9. 44. Al-Daghri NM, Alkharfy KM, Rahman S, Amer OE, Vinodson B, Sabico S, Piya MK, Harte AL, McTernan PG, Alokail MS, Chrousos GP. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects. Eur J Clin Invest. 2014;44(2):119–24. 45. Osthus IB, Sgura A, Berardinelli F, Alsnes IV, Bronstad E, Rehn T, Stobakk PK, Hatle H, Wisloff U, Nauman J.Telomere length and long-term endurance exercise: does exercise training affect biological age? A pilot study. PLoS One 2012, 7:e52769. 46. Sharma N, Castorena CM, Cartee GD. Greater insulin sensitivity in calorie restricted rats occurs with unaltered circulating levels of several important myokines and cytokines. Nutr Metab (Lond) 2012; 9:90. 47. Rana KS, Arif M, Hill EJ, Alfred S, Nagel DA, Nevill A, Randeva HS, Bailey CJ, Bellary S, Brown JE. Plasma Irisin levels predict telomere length in healthy adults. Age 2014;36:995-1001. 48. Lecker SH, Zavin A, Cao P, Arena R, Allsup K, Daniels KM, Joseph J, Schulze PC, Forman DE. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail. 2012;5:812–8. 49. Raschke S, Eckel J. Adipo-myokines: two sides of the same coin– mediators of inflammation and mediators of exercise. Mediators Inflamm V 2013, Article ID 320724, 16 pages. 50. Fisher JN, Ball EG. Studies on the metabolism of adipose tissue. XX. The effect of thyroid status upon oxygen consumption and lipolysis. Biochemistry 1967;6:637–47. 51. Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid 1995;5:481–92. 52. Ruchala M, Zybek A, Szczepanek-Parulska E.Serum irisin levels and thyroid function—Newly discovered association. Peptides 2014; 60: 51–5. 53. Moon HS, Mantzoros CS, Regulation of cell proliferation and malignant potential by irisin in endometrial, colon, thyroid and esophageal cancer cell lines. Metabolism 2014; 63 (2): 188-93. 54. Gannon NP, Roger A. Vaughan RA, Garcia-Smith R, Marco Bisoffi M, Trujillo KA. Effects of the exercise-inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer 2015; 136: E197- 202. 55. Mazur-Bialy AI, Oplawski M, Wypasek E, Zarawski M. Irisin – A newly discovered adipomiokine – Impairs growth and progression of breast cancer MDA-MB-231 cell line. Cytokine, 2015; 76:107. 56. Cunha A. basic research: Irisin Behind the benefits of ex- Actualizaciones sobre “Irisina”: la nueva mioquina


Sochinut_43_3
To see the actual publication please follow the link above